Pharmaceutical companies have re-emerged as "a wave of layoffs", with companies laying off 100 people and suspending research and development of new drugs

Ironwood Pharmaceuticals recently announced that it is restructuring its organizational structure, including cutting up to 100 full-time employees and suspending research and development of its refroutable gastroesoesic reflow disease (GERD) drug IW-3718.
ironwood plans to lay off nearly 35 percent of its workforce and is expected to complete it in the first quarter of 2021, according to the announcement.
said the job cuts would save about $95 million in total costs, leaving Ironwood with about 210 full-time employees.
addition to layoffs, Ironwood will suspend the development of IW-3718 and patient recruitment for Phase II trial IW-3718-301.
, staff said the layoffs and suspension of drug development were a reallocatory of resources and capital for Ironwood's business development needs.
Ironwood believes that by streamlining the organization, it can better position itself in the current environment and drive further growth and profitability.
addition to Ironwood, Teva recently announced it would cut 350 jobs at its Active Drug Ingredients (API) plant in Neot-Havav, Israel.
is understood to be part of Teva's Global Optimization Programme, which aims to streamline site operations and staff by February 2022.
fact, from the current pharmaceutical industry background, due to market competition, rising costs and the impact of this year's special period, the global pharmaceutical companies are facing greater revenue pressure, the need to reduce costs.
this year, a number of pharmaceutical companies have been out of the news of pay cuts and layoffs, in which pharmaceutical representatives have even become the "regulars" on the layoff list.
such as March 11, Abao Pharmaceutical Group informed that in order to ensure the implementation of the company's business activities in difficult times, reduce cash flow pressure, all staff to carry out short-term pay reduction.
, the monthly salaries of senior, middle and grass-roots staff were reduced by 20 per cent, 15 per cent and 10 per cent, respectively.
do not agree with the local dismissal of employees who have been paid a reduced salary.
April 7th Sage Therapeutics, a US biopharmaceutical company, announced a restructuring plan that would include 340 job cuts, or 53 per cent of the company's workforce.
that most of the employees who left were marketing and sales staff for Sage's listed products and the postpartum depression drug Zurresso, commonly known as brexanolone.
June 26th Sanofi, a leading French pharmaceutical company, announced that it would cut 1,680 jobs in Europe, including about 1,000 in France.
sources said Sanofi's job cuts were aimed at saving costs and improving operational efficiency.
as a whole, the main reasons for the layoffs of pharmaceutical companies are the reallocatement of resources and capital for the needs of business development.
refore, it can also be seen that the aim of pharmaceutical companies is not to "lay off" itself, but to use the subtract effect to code the core business, and for new therapies, such as gene therapy, quasi-treatment and so on.
In short, in the context of medical reform, the pharmaceutical landscape changes inevitably, with large pharmaceutical companies have focused on the company's key business and innovative drug channels, consolidate market position, its related actions, is bound to continue to affect the global pharmaceutical landscape.
Against this background, domestic pharmaceutical companies need to adjust their talent structure according to market trends and their own needs, while in the context of innovative drugs and high-end generic drugs becoming the new research and development direction, pharmaceutical companies need to speed up the recruitment and training of those pharmaceutical companies really need high-level personnel to become the main force in the development of domestic pharmaceutical enterprises.